Literature DB >> 34221829

Immunohistochemistry and RNA-sequencing have been useful in evaluating the pathological significance of a non-consensus site intronic variant in suspected cases of Lynch syndrome.

Toshiya Nishikubo1,2, Kaoru Masui2, Fumikazu Koyama3, Tomoko Uchiyama4, Chiho Ohbayashi4, Kazuo Tamura5.   

Abstract

Immunohistochemistry of mismatch repair proteins is a universal strategy for Lynch syndrome screening. In this case, Lynch syndrome was suspected, because MLH1 and PMS2 expression was negative by IHC. However, mismatch repair genetic analysis revealed a variant of unknown significance of c.454-13A > G in MLH1. Therefore, we performed reverse transcription-PCR using mRNA extracted from the patient's lymphocytes and detected a heterozygous gene allele indicating splicing abnormalities that complex splicing, with exon 5 followed by only the first codon (ACG) of exon 6 and leading to exon 7 of the MLH1. Two years later, this mutation was corrected to "likely pathogenic". For Lynch syndrome in which mismatch repair protein expression is undetectable by immunohistochemistry, reverse transcription-PCR may be useful to identify an intronic variant of unknown significance as the likely pathogenic variant. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  MLH1; Non-consensus site; Reverse transcription-PCR; Splicing defect; Variants of unknown significance

Year:  2021        PMID: 34221829      PMCID: PMC8206292          DOI: 10.1007/s13691-021-00474-2

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  11 in total

1.  Statistical features of human exons and their flanking regions.

Authors:  M Q Zhang
Journal:  Hum Mol Genet       Date:  1998-05       Impact factor: 6.150

2.  MLH1 intronic variants mapping to + 5 position of splice donor sites lead to deleterious effects on RNA splicing.

Authors:  Tamara Alejandra Piñero; Omar Soukarieh; Marion Rolain; Karin Alvarez; Francisco López-Köstner; Giovana Tardin Torrezan; Dirce Maria Carraro; Ivana Lucia De Oliveira Nascimento; Thaís Ferreira Bomfim; Taísa Manuela Bonfim Machado-Lopes; Juliana Côrtes Freitas; Maria Betânia Toralles; Kiyoko Abe Sandes; Benedito Mauro Rossi; Samuel Aguiar Junior; Joanna Meira; Mev Dominguez-Valentin; Pål Møller; Carlos Alberto Vaccaro; Alexandra Martins; Walter Hernán Pavicic
Journal:  Fam Cancer       Date:  2020-10       Impact factor: 2.375

Review 3.  Immunohistochemistry in screening for heritable colorectal cancer: what to do with an abnormal result.

Authors:  Steven R Paredes; Charles Chan; Matthew J F X Rickard
Journal:  ANZ J Surg       Date:  2019-12-11       Impact factor: 1.872

4.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

Review 5.  Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome.

Authors:  Kazuo Tamura; Motohide Kaneda; Mashu Futagawa; Miho Takeshita; Sanghyuk Kim; Mina Nakama; Norihito Kawashita; Junko Tatsumi-Miyajima
Journal:  Int J Clin Oncol       Date:  2019-07-04       Impact factor: 3.402

6.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Authors:  Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Hidewaki Nakagawa; Kaisa Sotamaa; Thomas W Prior; Judith Westman; Jenny Panescu; Dan Fix; Janet Lockman; Ilene Comeras; Albert de la Chapelle
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

7.  RNA-based mutation screening in hereditary nonpolyposis colorectal cancer.

Authors:  M Kohonen-Corish; V L Ross; W F Doe; D A Kool; E Edkins; I Faragher; J Wijnen; P M Khan; F Macrae; D J St John
Journal:  Am J Hum Genet       Date:  1996-10       Impact factor: 11.025

Review 8.  Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.

Authors:  Tristan Snowsill; Helen Coelho; Nicola Huxley; Tracey Jones-Hughes; Simon Briscoe; Ian M Frayling; Chris Hyde
Journal:  Health Technol Assess       Date:  2017-09       Impact factor: 4.014

Review 9.  Update on Lynch syndrome genomics.

Authors:  Päivi Peltomäki
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

10.  Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.

Authors:  Mev Dominguez-Valentin; Julian R Sampson; Toni T Seppälä; Sanne W Ten Broeke; John-Paul Plazzer; Sigve Nakken; Christoph Engel; Stefan Aretz; Mark A Jenkins; Lone Sunde; Inge Bernstein; Gabriel Capella; Francesc Balaguer; Huw Thomas; D Gareth Evans; John Burn; Marc Greenblatt; Eivind Hovig; Wouter H de Vos Tot Nederveen Cappel; Rolf H Sijmons; Lucio Bertario; Maria Grazia Tibiletti; Giulia Martina Cavestro; Annika Lindblom; Adriana Della Valle; Francisco Lopez-Köstner; Nathan Gluck; Lior H Katz; Karl Heinimann; Carlos A Vaccaro; Reinhard Büttner; Heike Görgens; Elke Holinski-Feder; Monika Morak; Stefanie Holzapfel; Robert Hüneburg; Magnus von Knebel Doeberitz; Markus Loeffler; Nils Rahner; Hans K Schackert; Verena Steinke-Lange; Wolff Schmiegel; Deepak Vangala; Kirsi Pylvänäinen; Laura Renkonen-Sinisalo; John L Hopper; Aung Ko Win; Robert W Haile; Noralane M Lindor; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; Jane C Figueiredo; Stephen N Thibodeau; Karin Wadt; Christina Therkildsen; Henrik Okkels; Zohreh Ketabi; Leticia Moreira; Ariadna Sánchez; Miquel Serra-Burriel; Marta Pineda; Matilde Navarro; Ignacio Blanco; Kate Green; Fiona Lalloo; Emma J Crosbie; James Hill; Oliver G Denton; Ian M Frayling; Einar Andreas Rødland; Hans Vasen; Miriam Mints; Florencia Neffa; Patricia Esperon; Karin Alvarez; Revital Kariv; Guy Rosner; Tamara Alejandra Pinero; María Laura Gonzalez; Pablo Kalfayan; Douglas Tjandra; Ingrid M Winship; Finlay Macrae; Gabriela Möslein; Jukka-Pekka Mecklin; Maartje Nielsen; Pål Møller
Journal:  Genet Med       Date:  2019-07-24       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.